PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1397675-3 1992 Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a. Zidovudine 12-22 interferon alpha 2 Homo sapiens 140-159 9402071-10 1997 The addition of interferon-alpha2a to zidovudine and zalcitabine resulted in transient enhanced decreases in viral load and increased toxicity. Zidovudine 38-48 interferon alpha 2 Homo sapiens 16-34 8820601-1 1995 Previous experimental studies utilizing human recombinant interferon-alpha-2b (IFNalpha-2b) alone or with zidovudine (AZT) to treat established feline leukemia virus (FeLV) infection resulted in a significant reduction in circulating virus throughout a 49-day treatment period. Zidovudine 118-121 interferon alpha 2 Homo sapiens 58-77 8399067-1 1993 Previous experimental studies utilizing human recombinant interferon-alpha-2b (IFN alpha-2b) alone or with zidovudine (AZT) to treat established feline leukemia virus (FeLV) infection resulted in a significant reduction in circulating virus throughout a 49-day treatment period. Zidovudine 107-117 interferon alpha 2 Homo sapiens 58-77 8399067-1 1993 Previous experimental studies utilizing human recombinant interferon-alpha-2b (IFN alpha-2b) alone or with zidovudine (AZT) to treat established feline leukemia virus (FeLV) infection resulted in a significant reduction in circulating virus throughout a 49-day treatment period. Zidovudine 119-122 interferon alpha 2 Homo sapiens 58-77 1397675-3 1992 Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a. Zidovudine 12-22 interferon alpha 2 Homo sapiens 258-277 1397675-3 1992 Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a. Zidovudine 121-131 interferon alpha 2 Homo sapiens 258-277 1397675-3 1992 Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a. Zidovudine 121-131 interferon alpha 2 Homo sapiens 258-277 1397675-3 1992 Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a. Zidovudine 121-131 interferon alpha 2 Homo sapiens 258-277 1377102-3 1992 Interferon-alpha-2a and interferon-beta also exerted synergistic effects with azidothymidine, but the potentiation was weaker than that by the combination of interferon-gamma and aziodthymidine. Zidovudine 78-92 interferon alpha 2 Homo sapiens 0-19 2159992-1 1990 This study was undertaken to calculate the in vivo drug interactions between recombinant human interferon-alpha A/D (rHuIFN-alpha A/D) and 3"-azido-3"-deoxythymidine (AZT) in a quantitative model for retroviral viremia. Zidovudine 139-165 interferon alpha 2 Homo sapiens 95-115 2159992-1 1990 This study was undertaken to calculate the in vivo drug interactions between recombinant human interferon-alpha A/D (rHuIFN-alpha A/D) and 3"-azido-3"-deoxythymidine (AZT) in a quantitative model for retroviral viremia. Zidovudine 167-170 interferon alpha 2 Homo sapiens 95-115